Pharma Roundup: Novo Nordisk's Growth Strategy, Disclosure at Cleveland and Penn, and More

Novo CEO looks to Americas, Europe for growth — Bucking the general trend for pharma to expand in the developing world, Lars Sorensen, CEO of Denmark’s Novo Nordisk,told Forbes that the company was “going to see our main growth in the U.K., the U.S., Central Europe and Australia, as these countries use considerable resources to deal with inflammatory diseases.” Novo’s strength has lain with diabetes treatments, but inflammatory diseases are a new focus. [Source: Forbes, via FiercePharma]

A big week for disclosure — Both the Cleveland Clinic and the medical center at Penn will disclose the relationships their physicians have with pharmaceuticals companies, it was announced this week. [Source: Pharmalot]

22 UK biotech leaders request hundreds of millions of government pounds — Industry bigwigs are calling for a public-private partnership to reinvigorate a sector hard-hit by the present economy.  [Source: PharmaTimes]